Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)-Reference-Cited by-同舟云学术

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)

Published:2014-06-20 Issue:11 Volume:74 Page:2006-2015
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

Isenberg David,Gordon Caroline,Licu Daiana,Copt Samuel,Rossi Claudia Pena,Wofsy David

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference21 articles.

1. Assessment of lupus nephritis cohort over a 30-year period;Croca;Rheumatology,2011

2. B cells in systemic lupus erythematosus;Stamatis-Nick,2007

3. B cell elimination in systemic lupus erythematosus;Furtado;Clin Immunol,2013

4. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial;Merrill;Arthritis Rheum,2010

Cited by 243 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases;Journal of Autoimmunity;2024-09

2. Targeting APRIL in the treatment of glomerular diseases;Kidney International;2024-09

3. Modern treatment options for systemic lupus erythematosus in children (literature review);Modern Rheumatology Journal;2024-08-21

5. Past and present discovery of the BAFF/APRIL system – A bibliometric study from 1999 to 2023;Cellular Signalling;2024-08